Insights on the Radiopharmaceutical Global Industry to 2027 – Drivers, Restraints, Opportunities and Threats – GlobeNewswire

June 29, 2020 06:34 ET | Source: Research and Markets

Dublin, June 29, 2020 (GLOBE NEWSWIRE) -- The "Radiopharmaceutical - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Radiopharmaceutical market accounted for $3.76 billion in 2019 and is expected to reach $5.99 billion by 2027 growing at a CAGR of 6.0% during the forecast period. Some of the key factors propelling market growth are technological advancements in the diagnostics sector, increasing prevalence of cancer, and increasing applications of molecular imaging. However, the short half-life of radioisotopes is the restraining factor for the growth of the market.

Pharmaceutical formulations that contain radioisotopes are known as radiopharmaceuticals. These are bound with the biological molecules and are targeted for the specific organs. The molecules resulting from these formulations find a wide range of applications in the therapeutic and diagnostic sectors.

By radioisotope, the Technetium-99 segment is expected to grow at a significant market share during the forecast period owing to its easy availability and extensive diagnostic applications. Based on geography, North America is anticipated to hold considerable market share during the forecast period owing to the presence of radioisotope sources in the region.

Some of the key players in Radiopharmaceutical Market include Lantheus Medical Imaging, Inc, GE Healthcare, Advanced Accelerator Applications, Mallinckrodt, Bayer AG, Siemens Healthineers, IBA Radiopharma Solutions, Eckert & Ziegler, Philips, Jubilant Life Sciences Limited, Novartis AG, BWX Technologies, Inc., POLATOM, JSC Isotope, NTP Radioisotopes SOC Ltd, Curium, Australian Nuclear Science and Technology Organization (ANSTO), Cardinal Health Inc., Covidien Plc, Positron Corporation, Monrol Nuclear Products,Inc, and Nordion, Inc.

Sources Covered:

Types Covered:

Radioisotopes Covered:

Applications Covered:

End Users Covered:

Regions Covered:

North America

Europe

Asia Pacific

South America

Middle East & Africa

What the report offers:

Key Topics Covered:

1 Executive Summary

2 Preface 2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology 2.4.1 Data Mining 2.4.2 Data Analysis 2.4.3 Data Validation 2.4.4 Research Approach 2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions

3 Market Trend Analysis 3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 Application Analysis 3.7 End User Analysis 3.8 Emerging Markets 3.9 Impact of Covid-19

4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry

5 Global Radiopharmaceutical Market, By Source 5.1 Introduction 5.2 Nuclear Reactors 5.3 Cyclotrons

6 Global Radiopharmaceutical Market, By Type 6.1 Introduction 6.2 Therapeutic 6.2.1 Alpha Emitters 6.2.2 Beta Emitters 6.2.3 Brachytherapy Isotopes 6.3 Diagnostic 6.3.1 Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals 6.3.2 Positron Emission Tomography (PET) Radiopharmaceuticals

7 Global Radiopharmaceutical Market, By Radioisotope 7.1 Introduction 7.2 Yttrium-90 7.3 Thallium-201 7.4 Technetium-99 7.5 Strontium -89 7.6 Samarium-153 7.7 Rubidium-82 7.8 Rhenium-186 7.9 Radium-223 7.10 Palladium - 103 7.11 Leutetium-177 7.12 Iridium - 192 7.13 Iodine-131 7.14 Iodine-125 7.15 Iodine-123 7.16 Indium-111 7.17 Holmium-166 7.18 Gallium-68 7.19 Gallium-67 7.20 Fluorine-18 7.21 Fludeoxyglucose - (18F-FDG) 7.22 Erbium-169 7.23 Cesium-131

7.24 Actinium-225

8 Global Radiopharmaceutical Market, By Application 8.1 Introduction 8.2 Thyroid 8.3 Theranostics 8.4 Oncology 8.5 Neurology 8.6 Neuroendocrinology 8.7 Nephrology 8.8 Lymphoma 8.9 Inflammation 8.10 Gastroenterology 8.11 Cardiology

9 Global Radiopharmaceutical Market, By End User 9.1 Introduction 9.2 Ambulatory Surgical Centers 9.3 Cancer Research Institute 9.4 Diagnostic Imaging Centers 9.5 Hospitals

10 Global Radiopharmaceutical Market, By Geography 10.1 Introduction 10.2 North America 10.2.1 US 10.2.2 Canada 10.2.3 Mexico 10.3 Europe 10.3.1 Germany 10.3.2 UK 10.3.3 Italy 10.3.4 France 10.3.5 Spain 10.3.6 Rest of Europe 10.4 Asia Pacific 10.4.1 Japan 10.4.2 China 10.4.3 India 10.4.4 Australia 10.4.5 New Zealand 10.4.6 South Korea 10.4.7 Rest of Asia Pacific 10.5 South America 10.5.1 Argentina 10.5.2 Brazil 10.5.3 Chile 10.5.4 Rest of South America 10.6 Middle East & Africa 10.6.1 Saudi Arabia 10.6.2 UAE 10.6.3 Qatar 10.6.4 South Africa 10.6.5 Rest of Middle East & Africa

11 Key Developments 11.1 Agreements, Partnerships, Collaborations and Joint Ventures 11.2 Acquisitions & Mergers 11.3 New Product Launch 11.4 Expansions 11.5 Other Key Strategies

12 Company Profiling 12.1 Lantheus Medical Imaging, Inc 12.2 GE Healthcare 12.3 Advanced Accelerator Applications 12.4 Mallinckrodt 12.5 Bayer AG 12.6 Siemens Healthineers 12.7 IBA Radiopharma Solutions 12.8 Eckert & Ziegler 12.9 Philips 12.10 Jubilant Life Sciences Limited 12.11 Novartis AG 12.12 BWX Technologies, Inc. 12.13 POLATOM 12.14 JSC Isotope 12.15 NTP Radioisotopes SOC Ltd 12.16 Curium 12.17 Australian Nuclear Science and Technology Organization (ANSTO) 12.18 Cardinal Health Inc. 12.19 Covidien Plc 12.20 Positron Corporation 12.21 Monrol Nuclear Products,Inc 12.22 Nordion, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/2h966q

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original here:
Insights on the Radiopharmaceutical Global Industry to 2027 - Drivers, Restraints, Opportunities and Threats - GlobeNewswire